Chimerix, Inc. (CMRX)
| Market Cap | 194.58M |
| Revenue (ttm) | 33.06M |
| Net Income (ttm) | 153.63M |
| Shares Out | 87.63M |
| EPS (ttm) | 1.69 |
| PE Ratio | 1.15 |
| Forward PE | 1.21 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,800,788 |
| Open | 2.13 |
| Previous Close | 2.21 |
| Day's Range | 1.95 - 2.17 |
| 52-Week Range | 1.27 - 7.42 |
| Beta | 1.14 |
| Analysts | Buy |
| Price Target | 7.65 (+292.3%) |
| Earnings Date | Nov 3, 2022 |
About CMRX
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic... [Read more]
Financial Performance
In 2021, Chimerix's revenue was $1.98 million, a decrease of -63.16% compared to the previous year's $5.37 million. Losses were -$173.24 million, 298.0% more than in 2020.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for CMRX stock is "Buy." The 12-month stock price forecast is 7.65, which is an increase of 292.31% from the latest price.
News
Chimerix Announces Successful Launch of ONC201 Phase 3 ACTION Study at Society for Neuro-Oncology Conference and Prov...
– Natural Disease History study indicates median overall survival in recurrent H3 K27M-mutant diffuse glioma of 5.1 months compared to 13.7 months in the prior ONC201 Phase 2 efficacy analysis –
Chimerix (CMRX) Upgraded to Buy: What Does It Mean for the Stock?
Chimerix (CMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Chimerix Responds to Rubric Capital Management
Highlights Confidence in Ongoing Strategy and Future Clinical Development Plans Highlights Confidence in Ongoing Strategy and Future Clinical Development Plans
Rubric Capital Management Sends Letter to Chimerix Board of Directors
NEW YORK--(BUSINESS WIRE)--Rubric Capital Management LP (“Rubric”), an investment adviser whose managed funds and accounts collectively own approximately 8.5% of the common stock of Chimerix, Inc. (“Chi...
Buy 3 of the Best Stocks by Using Net Income Ratio
Chimerix (CMRX), Vista Oil & Gas (VIST) and Arcus Biosciences (RCUS) have been selected as the top picks with a high net income ratio.
Chimerix (CMRX) Beats Q3 Earnings Estimates
Chimerix (CMRX) delivered earnings and revenue surprises of 30.95% and 84.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Chimerix Reports Third Quarter 2022 Financial Results and Provides Operational Update
– ONC201 Phase 3 ACTION Study On-Track to Open Enrollment in November –
Chimerix to Report Third Quarter 2022 Financial Results and Provide an Operational Update on November 3, 2022
DURHAM, N.C., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend lives of patients facing de...
Chimerix (CMRX) Earnings Expected to Grow: What to Know Ahead of Q3 Release
Chimerix (CMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chimerix Announces Closing of TEMBEXA Sale to Emergent BioSolutions
- $238 Million in Upfront Payment Received at Closing with Additional $136.5 Million in Potential Milestone Payments Plus Royalties -
Chimerix to Present at H.C. Wainwright 24th Annual Global Investment Conference
DURHAM, N.C., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients f...
Chimerix Awarded BARDA Contract for TEMBEXA as Medical Countermeasure for Smallpox
- Initial Procurement of 319,000 Treatment Courses for $115M with Additional Procurements at BARDA's Discretion Over 10 Years –
7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher
Monkeypox stocks, our topic for today, have had a mostly mixed performance so far in 2022. It is likely, however, that they could benefit from the similar tailwinds enjoyed by companies, such as Pfizer ...
Chimerix Reports Second Quarter 2022 Financial Results and Provides Operational Update
– ONC201 Phase 3 ACTION Study Planned to Initiate This Year –
Chimerix to Report Second Quarter 2022 Financial Results and Provide an Operational Update on August 8, 2022
DURHAM, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend lives of patients facing de...
Monkeypox Stocks SIGA, GOVX, BVNRY, CHMX, EBS Soar on Global Health Emergency
Drugs and vaccines used against smallpox are seen as the first line of defense against the rising tide of monkeypox infections. The post Monkeypox Stocks SIGA, GOVX, BVNRY, CHMX, EBS Soar on Global Heal...
Monkeypox Stocks BVNRY, EBS, CMRX, SIGA Heat Up on U.S. Vaccine Stockpile
Stocks related to the treatment of monkeypox are heating up today on news that the U.S. is building a vaccine stockpile and will offer vaccine appointments to individuals who are at risk of contracting ...
Chimerix Announces TEMBEXA Procurement Agreement for Approximately $25.3 Million with Public Health Agency of Canada
DURHAM, N.C., June 24, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients fa...
Chimerix Announces $9.3 Million International TEMBEXA Procurement Agreement
DURHAM, N.C., June 23, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients fa...
7 Penny Stocks That Could Triple in 2022
Some stocks currently trading in penny stock territory have unique advantages that makes it worthwhile to overlook the inherent risk involved in investing in these stocks. The post 7 Penny Stocks That C...
7 Monkeypox Stocks That May Take Off in Q2
SIGA Technologies (SIGA) may lead on the list of monkeypox stocks that could soar, but Bavarian Nordic seems to be leading the sales race. The post 7 Monkeypox Stocks That May Take Off in Q2 appeared fi...
Chimerix to Present at Jefferies Global Healthcare Conference
DURHAM, N.C., June 01, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients fa...
Vaccine-maker shares soar on monkeypox outbreak
CNBC's Meg Tirrell joins 'Squawk Box' to break down the companies with vaccines against monkeypox as multiple countries respond to a growing number of cases.
Are These 4 Stocks Smart Buys With the Monkeypox Outbreak?
The monkeypox opportunity could already be baked into the prices of these stocks.